BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26048310)

  • 1. Aloe-emodin exerts a potent anticancer and immunomodulatory activity on BRAF-mutated human melanoma cells.
    Tabolacci C; Cordella M; Turcano L; Rossi S; Lentini A; Mariotti S; Nisini R; Sette G; Eramo A; Piredda L; De Maria R; Facchiano F; Beninati S
    Eur J Pharmacol; 2015 Sep; 762():283-92. PubMed ID: 26048310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor properties of aloe-emodin and induction of transglutaminase 2 activity in B16-F10 melanoma cells.
    Tabolacci C; Lentini A; Mattioli P; Provenzano B; Oliverio S; Carlomosti F; Beninati S
    Life Sci; 2010 Aug; 87(9-10):316-24. PubMed ID: 20624404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.
    Fratangelo F; Camerlingo R; Carriero MV; Pirozzi G; Palmieri G; Gentilcore G; Ragone C; Minopoli M; Ascierto PA; Motti ML
    Int J Oncol; 2018 Sep; 53(3):1149-1159. PubMed ID: 29956724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
    Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
    Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aloe-emodin as antiproliferative and differentiating agent on human U937 monoblastic leukemia cells.
    Tabolacci C; Oliverio S; Lentini A; Rossi S; Galbiati A; Montesano C; Mattioli P; Provenzano B; Facchiano F; Beninati S
    Life Sci; 2011 Nov; 89(21-22):812-20. PubMed ID: 21978786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onconase Restores Cytotoxicity in Dabrafenib-Resistant A375 Human Melanoma Cells and Affects Cell Migration, Invasion and Colony Formation Capability.
    Raineri A; Fasoli S; Campagnari R; Gotte G; Menegazzi M
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31783660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effect of aloe-emodin on metastasis potential in HO-8910PM cell line.
    He TP; Yan WH; Mo LE; Liang NC
    J Asian Nat Prod Res; 2008; 10(5-6):383-90. PubMed ID: 18464074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
    Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
    Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
    Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
    J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations.
    Gentilcore G; Madonna G; Mozzillo N; Ribas A; Cossu A; Palmieri G; Ascierto PA
    BMC Cancer; 2013 Jan; 13():17. PubMed ID: 23317446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition.
    Phadke M; Remsing Rix LL; Smalley I; Bryant AT; Luo Y; Lawrence HR; Schaible BJ; Chen YA; Rix U; Smalley KSM
    Mol Oncol; 2018 Jan; 12(1):74-88. PubMed ID: 29112787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of Aloe emodin on invasion and metastasis of high metastatic breast cancer MDA-MB-231 cells].
    He ZH; Huang YQ; Weng SF; Tan YR; He TP; Qin YM; Liang NC
    Zhong Yao Cai; 2013 Sep; 36(9):1481-5. PubMed ID: 24620697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H; Quan H; Lou L
    Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.
    Paoluzzi L; Hanniford D; Sokolova E; Osman I; Darvishian F; Wang J; Bradner JE; Hernando E
    Cancer Med; 2016 Jun; 5(6):1183-93. PubMed ID: 27169980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aloin enhances cisplatin antineoplastic activity in B16-F10 melanoma cells by transglutaminase-induced differentiation.
    Tabolacci C; Rossi S; Lentini A; Provenzano B; Turcano L; Facchiano F; Beninati S
    Amino Acids; 2013 Jan; 44(1):293-300. PubMed ID: 22139409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.
    Hirschi B; Gallmeier E; Ziesch A; Marschall M; Kolligs FT
    Mol Cancer; 2014 May; 13():122. PubMed ID: 24885690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.
    Cavalieri S; Di Guardo L; Cimminiello C; Bono A; Tolomio E; Colombetti A; Valeri B; Di Tolla G; de Braud F; Del Vecchio M
    Tumori; 2016 Oct; 102(5):501-507. PubMed ID: 27470608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents.
    Zaidi S; Blanchard M; Shim K; Ilett E; Rajani K; Parrish C; Boisgerault N; Kottke T; Thompson J; Celis E; Pulido J; Selby P; Pandha H; Melcher A; Harrington K; Vile R
    Mol Ther; 2015 May; 23(5):845-856. PubMed ID: 25544599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
    Walter L; Heinzerling L
    Anticancer Res; 2018 Mar; 38(3):1335-1341. PubMed ID: 29491057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
    Dar AA; Nosrati M; Bezrookove V; de Semir D; Majid S; Thummala S; Sun V; Tong S; Leong SP; Minor D; Billings PR; Soroceanu L; Debs R; Miller JR; Sagebiel RW; Kashani-Sabet M
    J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.